Leading the Vanguard – Early Clinical Assessment of Biomarkers to Drive Development of Alzheimer’s Disease Therapies

Time: 2:30 pm
day: Day Two


  • Building a translational strategy to identify robust preclinical signals
  • Interrogating biomarkers by applying a translational pharmacology approach in Phase 1
  • Capitalizing on objective assessments to guide clinical development in early patient studies